Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
obatoclax + rituximab
- Development stage
- Phase 2
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Obatoclax + rituximab** is an investigational combination therapy studied primarily for hematological malignancies, such as chronic lymphocytic leukemia and B-cell lymphomas. **Obatoclax** is a small molecule BH3 mimetic that antagonizes anti-apoptotic BCL-2 family proteins (including Mcl-1, Bcl-XL, and Bcl-w), promoting cancer cell apoptosis. **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, inducing cell death via immune mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-mediated cytotoxicity (CMC), and direct apoptosis signaling. Obatoclax has shown the ability to augment rituximab-mediated ADCC and enhance anti-tumor effects in both rituximab-sensitive and -resistant models. Clinically, the combination has demonstrated promising activity in relapsed/refractory chronic lymphocytic leukemia and B-cell lymphoma, with acceptable tolerability profile in early-phase trials[1][2][4].
- Other names
- obatoclax + rituximab
02
Targets
CD20 (B-lymphocyte antigen CD20)BCL2L1 (B-cell lymphoma-extra large protein)MCL1 (Myeloid cell leukemia sequence 1)
Beyond the preview
Go deeper on obatoclax + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on obatoclax + rituximab.